PALO ALTO, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Telik, Inc. announced that preclinical data from its program to develop novel small molecule kinase inhibitors will be presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in San Francisco. The presentation, “In Vitro and Vivo Anticancer Activities of Dual Inhibitors of Aurora Kinases and VEGFR2" (Abstract # C206) will be on Thursday, October 25, 2007, at 12:30 pm Pacific time during the session “Small Molecule Therapeutic Agents: Kinase Inhibitors.”
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidates are TELCYTA(R), a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer; and TELINTRA(TM), which is in clinical development for the treatment of myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com.
CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications of
Telik, Inc., +1-650-845-7728, cdeguzman@telik.com
Web site: http://www.telik.com/
